Medicamen Biotech Limited (IN:MEDICAMEQ)
:MEDICAMEQ
Want to see IN:MEDICAMEQ full AI Analyst Report?
Top Page
Medicamen Biotech Limited
(MEDICAMEQ)
Select Model
Select Model
Rating:55Neutral
Price Target:
₹249.00
▼(-32.13% Downside)
Action:ReiteratedDate:03/13/26
The score is anchored by mixed financial performance: a solid balance sheet and decent operating margins are offset by weak cash generation (negative operating and free cash flow). Technicals further weigh on the rating due to a clear downtrend (below major moving averages and negative MACD). Valuation is also a headwind given the high P/E and minimal dividend yield.
Positive Factors
Solid balance sheet and moderate leverage
A reasonable debt-to-equity ratio and a solid equity ratio indicate durable solvency and financial flexibility. Satisfactory ROE shows management can generate returns from equity capital. This structural strength supports investment, borrowing capacity, and resilience across 2-6 months.
Negative Factors
Negative operating cash flow and negative free cash flow
Persistent negative operating and free cash flow undermines internal funding for capex, working capital, and R&D. Over 2-6 months this reduces financial flexibility, may force external financing or cutbacks, and raises execution risk for growth initiatives.
Read all positive and negative factors
Positive Factors
Negative Factors
Solid balance sheet and moderate leverage
A reasonable debt-to-equity ratio and a solid equity ratio indicate durable solvency and financial flexibility. Satisfactory ROE shows management can generate returns from equity capital. This structural strength supports investment, borrowing capacity, and resilience across 2-6 months.
Read all positive factors
Medicamen Biotech Limited (MEDICAMEQ) vs. iShares MSCI India ETF (INDA)
Market Cap
₹3.44B
Dividend Yield0.26%
Average Volume (3M)2.40K
Price to Earnings (P/E)56.5
Beta (1Y)1.43
Revenue Growth-7.50%
EPS Growth6.39%
CountryIN
Employees378
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)1.61
Shares Outstanding13,562,815
10 Day Avg. Volume3,620
30 Day Avg. Volume2,395
Financial Highlights & Ratios
PEG Ratio-2.50
Price to Book (P/B)2.95
Price to Sales (P/S)3.86
P/FCF Ratio-52.55
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Medicamen Biotech Limited Business Overview & Revenue Model
Company Description
Medicamen Biotech Limited manufactures and sells pharmaceutical formulations in India. The company offers its products in various forms, including tablets, capsules, liquid and dry syrups, and ointments. It also provides oral rehydration solution,...
How the Company Makes Money
Medicamen Biotech Limited makes money primarily by selling pharmaceutical formulations (finished dosage medicines) to customers in India and overseas. Revenue is generated from (1) domestic formulation sales through its marketing and distribution ...
Medicamen Biotech Limited Financial Statement Overview
Summary
Income Statement
68
Positive
Balance Sheet
75
Positive
Cash Flow
55
Neutral
| Breakdown | TTM | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.65B | 1.63B | 1.79B | 1.41B | 1.15B | 1.13B |
| Gross Profit | 634.54M | 389.90M | 852.01M | 687.74M | 479.88M | 335.16M |
| EBITDA | 210.79M | 201.02M | 245.66M | 277.12M | 258.07M | 204.25M |
| Net Income | 101.58M | 71.08M | 109.31M | 148.44M | 148.98M | 121.29M |
Balance Sheet | ||||||
| Total Assets | 3.67B | 2.97B | 2.95B | 2.79B | 2.26B | 1.94B |
| Cash, Cash Equivalents and Short-Term Investments | 436.79M | 37.59M | 147.86M | 207.79M | 38.25M | 38.91M |
| Total Debt | 386.49M | 332.53M | 311.12M | 257.09M | 257.96M | 188.19M |
| Total Liabilities | 916.99M | 841.04M | 875.67M | 851.03M | 792.24M | 611.18M |
| Stockholders Equity | 2.75B | 2.13B | 2.07B | 1.93B | 1.46B | 1.33B |
Cash Flow | ||||||
| Free Cash Flow | -145.81M | -119.32M | -130.31M | -128.94M | -44.99M | -51.94M |
| Operating Cash Flow | -124.06M | -98.59M | -67.44M | -62.93M | 41.09M | 127.72M |
| Investing Cash Flow | -15.21M | -23.78M | -55.63M | -58.80M | -84.73M | -178.13M |
| Financing Cash Flow | 538.49M | 12.16M | 63.13M | 291.27M | 42.98M | 58.39M |
Medicamen Biotech Limited Technical Analysis
Neutral
366.90
Price Trends
288.87
Negative
336.00
Negative
349.02
Negative
Market Momentum
-11.34
Negative
50.28
Neutral
55.48
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:MEDICAMEQ, the sentiment is Neutral. The current price of 366.9 is above the 20-day moving average (MA) of 244.13, above the 50-day MA of 288.87, and above the 200-day MA of 349.02, indicating a neutral trend. The MACD of -11.34 indicates Negative momentum. The RSI at 50.28 is Neutral, neither overbought nor oversold. The STOCH value of 55.48 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for IN:MEDICAMEQ.
Medicamen Biotech Limited Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
66 Neutral | ₹3.21B | 48.53 | ― | ― | -0.51% | 124.85% | |
64 Neutral | ₹3.53B | 36.55 | ― | ― | 26.44% | 31.04% | |
55 Neutral | ₹3.44B | 56.53 | ― | 0.26% | -7.50% | 6.39% | |
52 Neutral | ₹2.78B | 7.63 | ― | ― | -57.41% | -2188.42% | |
52 Neutral | ₹4.28B | -13.45 | ― | ― | 91.43% | 18.68% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | ₹4.11B | 6.87 | ― | 0.66% | -10.36% | -76.23% |
* Healthcare Sector Average
IN:MEDICAMEQ
Medicamen Biotech Limited
253.30
-178.65
-41.36%
IN:ALBERTDAVD
Albert David Ltd
720.05
-106.07
-12.84%
IN:BAFNAPH
Bafna Pharmaceuticals Limited
135.70
55.10
68.36%
IN:MEDICO
Medico Remedies Ltd.
42.50
-12.54
-22.78%
IN:NECLIFE
Nectar Lifesciences Ltd.
12.40
-9.41
-43.15%
IN:VALIANTLAB
Valiant Laboratories Ltd.
78.85
-13.83
-14.92%
Medicamen Biotech Limited Corporate Events
Medicamen Biotech Gets NSE Caution Over Compliance Observations
Feb 21, 2026
Medicamen Biotech Limited has disclosed that it received a cautionary letter from the National Stock Exchange of India on 27 January 2026, following observations made by its Secretarial Auditor in the annual Secretarial Compliance Report for the f...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.